Outcomes related to respiratory syncytial virus with an abbreviated palivizumab regimen in children with congenital heart disease: a descriptive analysis

BACKGROUND: It has been hypothesized that 4 doses of palivizumab, a neutralizing monoclonal antibody against respiratory syncytial virus (RSV), administered during a fixed-date RSV season may reduce hospital admissions comparably to the standard 5-dose schedule. We report outcomes in children with c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:CMAJ Open
Autors principals: Claydon, Jennifer, Popescu, Constantin R., Shaiba, Lana, Christopherson, Cheryl, Human, Derek, Taylor, Richard, Solimano, Alfonso, Lavoie, Pascal M.
Format: Artigo
Idioma:Inglês
Publicat: Joule Inc. or its licensors 2019
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6380901/
https://ncbi.nlm.nih.gov/pubmed/30782771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.9778/cmajo.20180167
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars